Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Charité Campus Virchow, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Breast Cancer Res Treat. 2012 Dec;136(3):789-94. doi: 10.1007/s10549-012-2311-2. Epub 2012 Nov 3.
Depression and anxiety are the core disorders causing emotional distress in patients (pts) with metastatic breast cancer. The aim of our study was to screen metastatic breast cancer outpatients for anxiety and depression, and to investigate the influence of age, Karnofsky Performance Status (KPS), cancer activity, and inflammation as represented by IL-6 levels on these two mood disorders. Pts treated with chemotherapy for metastatic breast cancer (n = 70) were assessed using the Hospital Anxiety and Depression Scale (HADS) for symptoms (scores 0-21) and caseness (score ≥11) of clinical depression and anxiety. Blood samples for IL-6 concentrations were collected at 10:00 a.m. A total of 22 (31.4 %) pts were diagnosed with caseness of clinical depression and 23 (32.9 %) pts with clinical anxiety, while 12 pts were diagnosed positive for both mood disorders. Depression and anxiety were positively but moderately correlated (Spearman's r (2) = 0.24, p < 0.001). IL-6 was significantly correlated with symptoms of depression (r (2) = 0.42, p < 0.001) and to a lesser extent to symptoms of anxiety (r (2) = 0.16, p = 0.001). In addition, IL-6 was positively associated with tumor progression (p < 0.001). Multiple linear regression analysis showed that tumor progression (standardized b = 0.226, p = 0.047), symptoms of anxiety (b = 0.292, p = 0.016), and IL-6 (b = 0.314, p = 0.007) were independently associated with clinical depression, whereas anxiety was linked to tumor progression (b = 0.238, p = 0.030), symptoms of depression (b = 0.407, p < 0.001) and age (b = -0.381, p < 0.001), but not to IL-6 (b = 0.168, p = 0.134). Even though a positive correlation between depression and anxiety exists, clinical parameters like age, cancer activity, KPS, and IL-6 do influence depression and anxiety differently. Unlike clinical depression, anxiety is not associated with increased IL-6 levels, however, shows a reciprocal correlation with age.
抑郁和焦虑是导致转移性乳腺癌患者情绪困扰的核心障碍。我们的研究目的是筛查转移性乳腺癌门诊患者的焦虑和抑郁,并探讨年龄、卡诺夫斯基表现状态(KPS)、癌症活动度以及以白细胞介素 6(IL-6)水平为代表的炎症对这两种情绪障碍的影响。采用医院焦虑抑郁量表(HADS)对接受化疗的 70 例转移性乳腺癌患者进行评估,评估症状(得分 0-21)和临床抑郁和焦虑的病例(得分≥11)。上午 10 点采集 IL-6 浓度的血液样本。共有 22 例(31.4%)患者被诊断为临床抑郁病例,23 例(32.9%)患者被诊断为临床焦虑病例,12 例患者同时被诊断为两种情绪障碍。抑郁和焦虑呈正相关,但相关性适中(Spearman's r(2)=0.24,p<0.001)。IL-6 与抑郁症状显著相关(r(2)=0.42,p<0.001),与焦虑症状的相关性较小(r(2)=0.16,p=0.001)。此外,IL-6 与肿瘤进展呈正相关(p<0.001)。多元线性回归分析显示,肿瘤进展(标准化 b=0.226,p=0.047)、焦虑症状(b=0.292,p=0.016)和 IL-6(b=0.314,p=0.007)与临床抑郁独立相关,而焦虑与肿瘤进展(b=0.238,p=0.030)、抑郁症状(b=0.407,p<0.001)和年龄(b=-0.381,p<0.001)相关,但与 IL-6 无关(b=0.168,p=0.134)。尽管抑郁和焦虑之间存在正相关,但年龄、癌症活动度、KPS 和 IL-6 等临床参数对抑郁和焦虑的影响不同。与临床抑郁不同,焦虑与升高的 IL-6 水平无关,但与年龄呈反向相关。